Lupin's Nagpur facility has received two observations from the USFDA through Form-483 due to violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company assured that it would resolve the issues raised and is confident of doing so soon. The USFDA conducted an inspection of the facility from July 3-11, 2023.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lCNGAfE
via IFTTT
0 comments:
Post a Comment